This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Eli Lilly & Company

Drug Names(s): EB10

Description: IMC-EB10 is an anti-FLT3 monoclonal antibody.

Deal Structure: In April 2003, Dyax announced that it entered into a second library license agreement with ImClone Systems effective March 31, 2003. The agreement provides ImClone Systems with a non-exclusive license to Dyax's new proprietaryantibody phage display library for the discovery of therapeutic antibodies and in-vitro diagnostics against ImClone Systems's diseasetargets. In return, Dyax has received an upfront license fee payment from ImClone Systems, and will continue to receive annual technologylicense fee payments for up to four years. Dyax will also receive clinical milestone payments and royalties on any therapeutic or diagnostic antibody products that results from ImClone Systems's use of the Dyax library.

ImClone Systems had previously licensed Dyax's original antibody phage library to successfully identify therapeutic antibody leads toKDR and two other undisclosed targets. Under the new agreement, Dyax's new library replaces theinitial library for phage antibody discovery. It...See full deal structure in Biomedtracker

Partners: Shire Pharmaceuticals Group PLC

IMC-EB10 News

Pink Sheet R&D IN BRIEF

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug